Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection.

de Bree GJ, Wheatley AK, Lynch RM, Prabhakaran M, Grijsen ML, Prins JM, Schmidt SD, Koup RA, Mascola JR, McDermott AB.

PLoS One. 2017 Mar 15;12(3):e0173577. doi: 10.1371/journal.pone.0173577. eCollection 2017.

2.

Evolution of B cell analysis and Env trimer redesign.

Karlsson Hedestam GB, Guenaga J, Corcoran M, Wyatt RT.

Immunol Rev. 2017 Jan;275(1):183-202. doi: 10.1111/imr.12515. Review.

PMID:
28133805
3.

An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.

Chen Y, Wilson R, O'Dell S, Guenaga J, Feng Y, Tran K, Chiang CI, Arendt HE, DeStefano J, Mascola JR, Wyatt RT, Li Y.

J Immunol. 2016 Nov 15;197(10):3982-3998. Epub 2016 Oct 10.

PMID:
27815444
4.

Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.

Pierce BG, Keck ZY, Lau P, Fauvelle C, Gowthaman R, Baumert TF, Fuerst TR, Mariuzza RA, Foung SK.

Proc Natl Acad Sci U S A. 2016 Oct 26. pii: 201614942. [Epub ahead of print]

PMID:
27791171
5.
6.

Maturational characteristics of HIV-specific antibodies in viremic individuals.

Meffre E, Louie A, Bannock J, Kim LJ, Ho J, Frear CC, Kardava L, Wang W, Buckner CM, Wang Y, Fankuchen OR, Gittens KR, Chun TW, Li Y, Fauci AS, Moir S.

JCI Insight. 2016;1(3). pii: e84610. Epub 2016 Mar 17.

7.

Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region.

Tolbert WD, Gohain N, Veillette M, Chapleau JP, Orlandi C, Visciano ML, Ebadi M, DeVico AL, Fouts TR, Finzi A, Lewis GK, Pazgier M.

Structure. 2016 May 3;24(5):697-709. doi: 10.1016/j.str.2016.03.005. Epub 2016 Mar 31.

8.

Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.

Madani N, Princiotto AM, Easterhoff D, Bradley T, Luo K, Williams WB, Liao HX, Moody MA, Phad GE, Vázquez Bernat N, Melillo B, Santra S, Smith AB 3rd, Karlsson Hedestam GB, Haynes B, Sodroski J.

J Virol. 2016 Apr 29;90(10):5031-46. doi: 10.1128/JVI.03211-15. Print 2016 May 15.

9.

Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.

Hessell AJ, Malherbe DC, Pissani F, McBurney S, Krebs SJ, Gomes M, Pandey S, Sutton WF, Burwitz BJ, Gray M, Robins H, Park BS, Sacha JB, LaBranche CC, Fuller DH, Montefiori DC, Stamatatos L, Sather DN, Haigwood NL.

J Immunol. 2016 Apr 1;196(7):3064-78. doi: 10.4049/jimmunol.1500527. Epub 2016 Mar 4.

10.

Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies.

Kaplan G, Roitburd-Berman A, Lewis GK, Gershoni JM.

J Virol. 2016 Apr 14;90(9):4481-93. doi: 10.1128/JVI.03206-15. Print 2016 May.

11.

A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.

Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A, Sanders RW, Moore JP, Bjorkman PJ, Seaman MS, Walker BD, Klein F, Nussenzweig MC.

PLoS Pathog. 2015 Oct 30;11(10):e1005238. doi: 10.1371/journal.ppat.1005238. eCollection 2015 Oct.

12.

Sequence variability is correlated with weak immunogenicity in Streptococcus pyogenes M protein.

Lannergård J, Kristensen BM, Gustafsson MC, Persson JJ, Norrby-Teglund A, Stålhammar-Carlemalm M, Lindahl G.

Microbiologyopen. 2015 Oct;4(5):774-89. doi: 10.1002/mbo3.278. Epub 2015 Jul 15.

13.

Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.

Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, McGuire AT, Kulp DW, Oliveira T, Scharf L, Pietzsch J, Gray MD, Cupo A, van Gils MJ, Yao KH, Liu C, Gazumyan A, Seaman MS, Björkman PJ, Sanders RW, Moore JP, Stamatatos L, Schief WR, Nussenzweig MC.

Cell. 2015 Jun 18;161(7):1505-15. doi: 10.1016/j.cell.2015.06.003.

14.

HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.

Jardine JG, Ota T, Sok D, Pauthner M, Kulp DW, Kalyuzhniy O, Skog PD, Thinnes TC, Bhullar D, Briney B, Menis S, Jones M, Kubitz M, Spencer S, Adachi Y, Burton DR, Schief WR, Nemazee D.

Science. 2015 Jul 10;349(6244):156-61. doi: 10.1126/science.aac5894. Epub 2015 Jun 18.

15.

Protein Crystallography in Vaccine Research and Development.

Malito E, Carfi A, Bottomley MJ.

Int J Mol Sci. 2015 Jun 9;16(6):13106-40. doi: 10.3390/ijms160613106. Review.

16.

Antibody responses to envelope glycoproteins in HIV-1 infection.

Burton DR, Mascola JR.

Nat Immunol. 2015 Jun;16(6):571-6. doi: 10.1038/ni.3158. Review.

17.

Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.

Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT.

J Virol. 2014 Dec;88(24):14002-16. doi: 10.1128/JVI.02614-14. Epub 2014 Sep 24. Erratum in: J Virol. 2015 Jun;89(12):6526.

18.

HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile.

Forsell MN, McKee K, Feng Y, Mascola JR, Wyatt RT.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1089-98. doi: 10.1089/AID.2014.0104.

19.

HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization.

Navis M, Tran K, Bale S, Phad GE, Guenaga J, Wilson R, Soldemo M, McKee K, Sundling C, Mascola J, Li Y, Wyatt RT, Karlsson Hedestam GB.

PLoS Pathog. 2014 Aug 28;10(8):e1004337. doi: 10.1371/journal.ppat.1004337. eCollection 2014 Aug.

20.

Design Challenges for HIV-1 Vaccines Based on Humoral Immunity.

Greenspan NS.

Front Immunol. 2014 Jul 16;5:335. doi: 10.3389/fimmu.2014.00335. eCollection 2014. Review. No abstract available.

Supplemental Content

Support Center